Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Update

Achilles Therapeutics plc (NASDAQ:ACHL) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 57,800 shares, a decrease of 52.8% from the January 15th total of 122,400 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 620,100 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Achilles Therapeutics stock. BML Capital Management LLC lifted its stake in shares of Achilles Therapeutics plc (NASDAQ:ACHL) by 555.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,100,002 shares of the company’s stock after purchasing an additional 3,474,828 shares during the period. Achilles Therapeutics comprises about 2.5% of BML Capital Management LLC’s investment portfolio, making the stock its 11th biggest holding. BML Capital Management LLC owned about 9.98% of Achilles Therapeutics worth $4,182,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 56.38% of the company’s stock.

Achilles Therapeutics Trading Up 0.7 %

ACHL stock opened at $1.39 on Friday. The firm has a 50 day simple moving average of $1.15 and a 200-day simple moving average of $0.99. The company has a market capitalization of $57.13 million, a P/E ratio of -0.84 and a beta of 1.32. Achilles Therapeutics has a twelve month low of $0.63 and a twelve month high of $1.76.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.